| González N, Aguilar L, Alou L, et al.
Influence of different resistance traits on the competitive growth of Haemophilus influenzae in antibiotic-free medium and selection of resistant populations by different {beta}-lactams: an in vitro pharmacodynamic approach. [JOURNAL ARTICLE]
J Antimicrob Chemother 2009 Mar 22.
Abstract | Full Citation | Find Related Articles | | Paris R, Confalonieri M, Dal Negro R, et al.
Efficacy and Safety of Azithromycin 1 g Once Daily for 3 Days in the Treatment of Community-Acquired Pneumonia: an Open-Label Randomised Comparison with Amoxicillin-Clavulanate 875/125 mg Twice Daily for 7 Days. [Journal Article]
J Chemother 2008 Feb; 20(1):77-86.
Abstract | Full Citation | | Nizam I, Kohan L, Kerr D
Nocardia nova septic arthritis following total knee replacement: a case report. [Journal Article]
J Orthop Surg (Hong Kong) 2007 Dec; 15(3):390-2.
Abstract | Full Citation | | Croisier D, Benoit M, Durand D, et al.
Efficacy of humanlike Augmentin SR (2000/125 mg) twice daily treatment on Haemophilus influenzae experimental pneumonia in rabbits. [Journal Article]
Scand J Infect Dis 2007; 39(2):115-21.
Abstract | Full Citation | Find Related Articles | | Alou L, Giménez MJ, Sevillano D, et al.
Are {beta}-lactam breakpoints adequate to define non-susceptibility for all Haemophilus influenzae resistance phenotypes from a pharmacodynamic point of view? [JOURNAL ARTICLE]
J Antimicrob Chemother 2007 Mar 6.
Abstract | Full Citation | Find Related Articles | | Bonifaz A, Flores P, Saúl A, et al.
Treatment of actinomycetoma due to Nocardia spp. with amoxicillin-clavulanate. [Journal Article]
Br J Dermatol 2007 Feb; 156(2):308-11.
Abstract | Full Citation | | Stein GE, Schooley S, Tyrrell KL, et al.
Human serum activity of telithromycin, azithromycin and amoxicillin/clavulanate against common aerobic and anaerobic respiratory pathogens. [JOURNAL ARTICLE]
Int J Antimicrob Agents 2007 Jan; 29(1):39-43.
Abstract | Full Citation | | Grossman RF, Ambrusz ME, Fisher AC, et al.
Levofloxacin 750 mg QD for five days versus amoxicillin/clavulanate 875 mg/125 mg BID for ten days for treatment of acute bacterial exacerbation of chronic bronchitis: A post hoc analysis of data from severely ill patients. [Journal Article]
Clin Ther 2006 Aug; 28(8):1175-80.
Abstract | Full Citation | | Siquier B, Sánchez-Alvarez J, García-Mendez E, et al.
Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae. [Journal Article, Randomized Controlled Trial]
J Antimicrob Chemother 2006 Mar; 57(3):536-45.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Martinez FJ, Grossman RF, Zadeikis N, et al.
Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: the role of levofloxacin 750 mg. [Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial]
Eur Respir J 2005 Jun; 25(6):1001-10.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |   |
|
| | Enter
www.unboundmedicine.com/medline
in your iPhone browser
or View our
Unbound MEDLINE
iPhone demo
Advertise on this site.
|
